Streetwise Reports' Article Archives — January 2023 back to current month (9)
New Drug for Hearing Loss Approved for Clinical Trials (01/30/2023)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
Biopharma Gains Another Shot on Goal With IND Approval (01/26/2023)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus (01/25/2023)
Streetwise Reports sat down with Řyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.
Med Tech Co. Well-Poised for Revenue Growth This Year (01/25/2023)
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.
Biopharma Creating COVID Drug Gets US$8.2M From the DOD (01/24/2023)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment (01/24/2023)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.
Exploring Why The Economist Named this Biotech 'One To watch' in 2023 (01/23/2023)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.
Telehealth Co. Expects More Growth in 2023 (01/20/2023)
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.
Biopharma Co.'s Burn Tissue Removal Product Approved (01/04/2023)
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec